Skip to content

Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01835860
Enrollment
13
Registered
2013-04-19
Start date
2013-03-31
Completion date
2015-12-31
Last updated
2016-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Prostate Hyperplasia

Keywords

BPH

Brief summary

To evaluate whether Prostatic Artery Embolization (PAE) might be an effective alternative treatment option for benign prostatic hyperplasia (BPH), in comparison to current gold standard surgical treatment- Transurethral Resection of Prostate (TURP).

Interventions

Sponsors

Saskatchewan Health Authority - Regina Area
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

1. Moderate to severe lower urinary tract symptoms (i.e. International prostate symptom score IPSS\>8) who are bothered by their symptoms (i.e., interfere with the daily activities of living) 2. Urinary retention (related to BPH) leading to catheterization. 3. Refractory to medical treatment or patient is not willing to consider medical treatment 4. Pre trans-urethral resection of prostate (TURP) to reduce the size of prostate gland if prostate is too big for TURP surgery.

Exclusion criteria

1. Mild symptoms (IPSS \<8) 2. Moderate to severe lower urinary tract symptoms (i.e. IPSS\>8) who are not bothered by their symptoms (i.e., symptoms do not interfere with the daily activities of living). 3. Suspected malignancy. 4. Any of the following clearly related to BPH- bladder stones, recurrent UTIs, and renal insufficiency. 5. Advanced atherosclerosis and unsuitable vascular access. 6. Allergy to intravenous contra

Design outcomes

Primary

MeasureTime frame
Change from baseline in symptom severity at 1, 3, 6 and 12 months follow-up, as measured by International prostate symptoms score (IPSS).1, 3, 6 and 12 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026